Background: Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D 2 (PGD 2 ). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD 2 , but it is unknown whether ILC2s are active in patients with AERD. Objective: We sought to determine whether ILC2 numbers change in peripheral blood and the nasal mucosa during COX-1 inhibitor-induced reactions in patients with AERD. Methods: Blood and nasal scrapings were collected at baseline, during reactions, and after completion of ketorolac/aspirin challenge/desensitization in 12 patients with AERD. ILC2s and eosinophils were quantitated by means of flow cytometry. Urine was also collected, and quantification of PGD 2 metabolite and leukotriene E 4 levels was done by using ELISA. Baseline and nonsteroidal anti-inflammatory drug reaction clinical data were correlated with cell changes. Results: ILC2 numbers significantly increased in nasal mucosal samples and decreased in blood at the time of COX-1 inhibitor reactions in 12 patients with AERD. These changes were not observed in 2 patients without AERD. Furthermore, eosinophil numbers decreased in blood concurrently with significant increases in urinary PGD 2 metabolite and leukotriene E 4 levels. The magnitude of increases in nasal mucosal ILC2 numbers positively correlated with maximum symptom scores during challenges. Furthermore, blood ILC2 numbers during the
Aspirin-exacerbated respiratory disease (AERD) is clinically characterized by a relentless progression of nasal congestion, anosmia, formation of nasal polyps, and, typically, asthma. Nasoocular and lower respiratory tract symptoms after ingestion of COX-1 inhibitors are pathognomonic for AERD. AERD is present in about 7% of adult asthmatic patients and 14% of patients with severe asthma 1 and can develop in patients without a prior history of atopy, asthma, or rhinitis. 2 Nasal polyps of patients with AERD are intensely eosinophilic and contain activated mast cells. 3, 4 The disease is characterized by release of large amounts of cysteinyl leukotrienes (CysLTs) and mast cell mediators, particularly prostaglandin D 2 (PGD 2 ), after COX-1 inhibitor ingestion. 5, 6 Recently, thymic stromal lymphopoietin (TSLP) and IL-33 have also been implicated in AERD pathogenesis. 7, 8 These 2 cytokines, in addition to PGD 2 and CysLTs, are known to promote group 2 innate lymphoid cell (ILC2) activation, [9] [10] [11] [12] and their presence suggests that ILC2s might be active in patients with AERD.
ILC2s are a recently described lymphocyte population that lack antigen specificity but are capable of producing large amounts of type 2 cytokines (IL-4, IL-5, IL-6, IL-9, and IL-13) and have been shown to promote type 2 inflammation. 13 In human subjects ILC2 numbers are increased in affected tissues from patients with atopic dermatitis, allergic asthma, eosinophilic esophagitis, and allergic rhinitis. [14] [15] [16] [17] [18] Importantly, ILC2 numbers are increased in nasal polyps and levels correlate with the degree of eosinophilia. 19 ILC2s are identified as lymphocytes that are lineage negative (ie, lacking the markers of B, T, or natural killer cells) and express chemoattractant receptor-homologous molecule expressed on T H 2 cells (CRTH2) and CD161. 3 CRTH2 is a G protein-coupled receptor that binds to PGD 2 , and PGD 2 has been shown to promote ILC2 chemotaxis and cytokine production in vitro. 10, 20 Thus these suggest a potential role for ILC2s in patients with AERD.
Our aim for this study was to determine ILC2 changes in the blood and nasal mucosa of patients with AERD during COX-1 inhibitor challenges. To our knowledge, there are no reports focused on a potential role for ILC2s in AERD-related nonsteroidal anti-inflammatory drug (NSAID)-induced reactions. Importantly, we found that ILC2 numbers were significantly increased in nasal scrapings and decreased in peripheral blood during the ketorolac-induced reactions in patients with AERD. These patients also had a corresponding decrease in blood eosinophil numbers, indicating that these processes happen simultaneously. Concomitantly, patients showed an increase in levels of 11b prostaglandin F2a (11b-PGF2a; a stable metabolite of PGD 2 ), 21 as well as the terminal CysLT leukotriene E 4 (LTE 4 ). Overall, this study implicates ILC2s as an additional cell type apart from mast cells and eosinophils that can contribute to AERD pathogenesis.
METHODS

Study subjects with AERD
Patients (n 5 14) undergoing aspirin desensitization for AERD at the Allergy Divisions of the University of California, San Diego and Scripps Clinic were recruited after institutional review board approval at both institutions. Informed consent was obtained from all patients before starting the study. All patients were suspected of having a diagnosis of AERD based on a history of nasal polyps and asthma and a compelling history of reactions to aspirin/NSAIDs within 2 to 3 hours. Demographic and clinical data were collected from retrospective chart review and included age, sex, ethnicity, asthma, and rhinoconjunctivitis characteristics; nasal polyp surgical details and clinical response; aspirin/NSAID reaction characteristics; current medications; and laboratory data. Symptom scores and spirometry were assessed at baseline. The modified AERD symptom scoring system included 8 symptoms (nasal congestion, runny nose, sneezing, itchy nose, itchy/watery eyes, tight throat, wheezing, and chest tightness), which the patients rated on a scale of 0 to 3 (range of possible scores, 0-24; see Fig E1 in this article's Online Repository at www.jacionline.org). Sino-Nasal Outcome Test 22 (SNOT-22) scores were recorded either that day or from a recent clinic visit.
Intranasal ketorolac and aspirin challenge/ desensitizations
Intranasal ketorolac and aspirin challenge/desensitizations were done per the standard protocol at each institution (see Fig E2 in this article's Online Repository at www.jacionline.org, which is adapted from Lee et al 22 ). Reactions were identified as any upper and/or lower respiratory tract signs or symptoms consistent with conjunctivitis, rhinitis, laryngospasm, and bronchospasm or decrease in FEV 1 .
Nasal scrapings, blood draws, and urine samples Nasal scraping was done with a Rhino-probe (Arlington Scientific, Springville, Utah) and involved 1 to 3 passes over the inferior turbinate on one side. Nasal scrapings were transported in RPMI for processing for flow cytometry to detect ILC2s. Blood was collected in BD vacutainers (BD Biosciences, San Diego, Calif) to quantitate ILC2 and eosinophil numbers. Samples, including nasal scrapings, blood, and urine, were collected at baseline. At the time of the first clinician-confirmed reaction, blood and a nasal scraping were again collected, and urine was collected 1 hour later. A third set of samples was collected at the end of the desensitization before patient discharge. Some patients were not able to provide all 3 samples. Symptom scores (per the system noted above), FEV 1 , and medications required were recorded at each time point. Urine samples were stored at 2808C. PGD 2 is metabolized to 11b-PGF 2 a, a stable active metabolite that is measurable in urine. 21 11b-PGF 2 a levels were analyzed by means of ELISA, according to the manufacturer's protocol (Cayman Chemical, Ann Arbor, Mich). Urinary LTE 4 levels were analyzed by means of ELISA, according to the manufacturer's protocol (Cayman Chemical). Values were corrected for specific gravity, as previously described. 23 
Identification of
Nasal polyps
Nasal polyps were collected from 2 subjects undergoing endoscopic sinus surgery at the University of California, San Diego who ultimately underwent desensitization for AERD and are included in that analysis. Tissue samples were transported in RPMI and processed for flow cytometry the same day. Nasal polyp tissue was digested with Collagenase Type 4 (Worthington, Lakewood, NJ) and DNase I (200 mg/mL; Roche, Indianapolis, Ind) and then filtered into a single-cell suspension. ILC2s were identified per above. GATA-3 1 cells were identified as CD45 
Statistical analyses
Statistical analysis was performed with GraphPad Prism software (GraphPad Software, La Jolla, Calif). The paired t test or Pearson correlation test were used, where indicated. A P value of less than .05 was considered statistically significant.
RESULTS
Demographics of patients with AERD and NSAID reaction characteristics
A total of 14 suspected patients with AERD were enrolled in the study. Baseline characteristics of patients are summarized in Table I . At the time of desensitization, 13 patients were receiving a leukotriene modifier for a minimum of 1 week; 1 patient was not receiving a leukotriene modifier because of adverse effects. Two (14%) patients were receiving daily oral corticosteroids. Eleven patients had typical COX-1 inhibitorinduced reactions, including bronchoconstriction and/or nasoocular symptoms, during ketorolac challenge. Three patients did not have reactions to ketorolac or aspirin challenge. One of the 3 patients had a history of recurrent aggressive nasal polyposis and severe asthma and was receiving omalizumab, which could possibly avert COX-1 inhibitor-induced exacerbations 24 ; this patient was determined to nonetheless have AERD (a ''silent reaction''). The 2 other patients had less consistent histories of reactions to COX-1 inhibitors, were not receiving omalizumab, and had no clinical response to aspirin. These 2 patients were determined not to have AERD and served as control subjects. One of these control subjects was the sole patient taking zileuton. ''Reaction'' samples for these 3 were taken after the final dose of ketorolac.
Identification of ILC2s in nasal scrapings and blood
Nasal polyp ILC2s have been previously reported as CD45 1 
Lin
2 lymphocytes that express CRTH2. 3, 19 To confirm our ILC2 gating strategy for nasal scrapings, we first stained nasal polyps from 2 patients with AERD, along with additional staining for the master T H 2 cytokine transcription factor GATA-3, as proof of concept that ILC2s are indeed identifiable in these patients (see Fig E3 in (Fig 1, A) . We did not use CD161 for tissue ILC2 staining to maintain consistency with what we had previously performed on nasal polyps. 19 Blood samples were separated into PBMCs and granulocytes, as described in the Methods section. ILC2s were obtained from the enriched PBMCs and identified as CD45 1 
2 lymphocytes that expressed CD161 and CRTH2 (Fig 1, B) . Isotype controls were done for all CRTH2 gating. Overall, we were able to identify ILC2s in blood and nasal scrapings of patients with AERD.
ILC2 numbers increase in nasal mucosa and decrease in blood from baseline values during COX-1 inhibitor challenge
The percentage of ILC2s of all cells in nasal scrapings increased significantly from baseline to those during COX-1 inhibitor-induced reaction (P 5 .001; Fig 2, A) . There was also a subsequent significant decrease in nasal scraping ILC2s from reaction to post-aspirin desensitization samples (P 5.004). Furthermore, blood ILC2 numbers decreased significantly from baseline to reaction samples (P 5 .031; Fig 2, B) . Representative baseline, reaction, and postdesensitization blood ILC2 plots are shown in Fig 1, C. The trend for blood ILC2 numbers to increase from reaction to postdesensitization samples approached but did not reach significance (P 5 .084). Changes in nasal scraping and blood ILC2 numbers were not seen in 2 control subject (Fig 2,  C) . The decrease in blood ILC2 numbers occurred concurrently with a significant decrease in blood eosinophil numbers from baseline to the time of reaction (P 5 .044; Fig 2, D) . Because of low nasal scraping cell numbers, we were able to identify eosinophils in only 2 patients. These 2 samples showed a 1.5-and 7.9-fold increase in nasal scraping eosinophils from baseline to reaction (3.34% to 5.01% reaction and 0.34% to 2.68%, respectively).
As expected, there was an increase in levels of the PGD 2 metabolite 11b-PGF 2 a and LTE 4 measured in urine during the COX-1 inhibitor-induced reaction (11b-PGF 2 a: P 5 .008 and LTE 4 : P 5 .017, difference between baseline and reaction samples; Fig 2, D and E) . The increases in urinary 11b-PGF 2 a and LTE 4 levels were observed at the same time as the increase in nasal scraping ILC2 numbers and decrease in blood ILC2 and eosinophil numbers. Baseline nasal scraping ILC2 numbers did not correlate with reaction levels of 11b-PGF 2 a (P 5 .12) or LTE 4 (P 5 .16). The magnitude of increase in nasal scraping ILC2 numbers did not correlate with the magnitude of increase in 11b-PGF 2 a (P 5 .105) or LTE 4 (P 5 .470) levels or the decrease in blood ILC2 (P 5.713) or eosinophil (P 5.281) numbers. Baseline blood ILC2 numbers negatively correlated with levels of reaction-associated urine 11b-PGF 2 a (R 2 5 0.559, P 5 .033) and LTE 4 (R 2 5 0.506, P 5 .048). The magnitude of the decrease in blood ILC2 numbers did not directly correlate with the magnitude of the decrease in blood eosinophil numbers (P 5 .536) or increase in 11b-PGF 2 a (P 5 .327) or LTE 4 (P 5 .064) levels. Thus, ILC2 numbers increase in the nasal mucosa and decrease in the blood during COX-1 inhibitor-induced reactions in patients with AERD. Nasal ILC2 numbers correlate with maximum symptom scores Symptom scores (evaluating upper and lower airway symptoms, as noted in the Methods section) were assessed at regular intervals during desensitization. Baseline SNOT-22 scores positively correlated with maximum symptom scores during desensitization (Pearson correlation coefficient, 2-tailed R 2 5 0.490, P 5 .036; Fig 3, A) . Baseline nasal scraping ILC2 levels were assigned a value of 1, and fold change was calculated from there. Interestingly, fold change from baseline to reaction in nasal ILC2 numbers positively correlated with maximum symptom scores (R 2 5 0.472, P 5 .028; Fig 3, B) . The percentage of ILC2s in blood negatively correlated with the maximum symptom score, although this fell short of significance (Pearson correlation coefficient, 2-tailed R 2 5 0.396, P 5 .051). Baseline nasal scraping and blood ILC2 numbers did not correlate with maximum symptom score (P 5 .95 and P 5 .21, respectively).
ILC2 numbers in the blood at the time of the reaction negatively correlated with the time it took for the reaction to subside (Pearson correlation coefficient, 2-tailed R 2 5 0.395, P 5 .038; Fig 3, C) . This might reflect that the more severe the reaction, the more ILC2s respond to stimuli to move out of the blood and into the tissues. Baseline nasal scraping and blood ILC2 numbers did not correlate with time for reaction to subside (P 5 .31 and .25, respectively). In those patients with symptoms on the final day of desensitization (skin, gastrointestinal, or respiratory) who required treatment, the average number of ILC2s in the blood was lower than in those without symptoms (although this trend fell short of significance; 0.027% vs 0.11%; P 5 .061, 2-tailed unpaired t test). Neither postdesensitization blood ILC2 nor eosinophil numbers correlated with time since reaction on day 1 or final dose of aspirin. ILC2 numbers on the last day did not differ if the patient received systemic corticosteroids during the reaction on day 1. We did not find a correlation between blood ILC2 numbers and the decrease in FEV 1 (P 5 .52). Reactionassociated nasal scraping or blood ILC2 numbers did not differ based on sex, age, atopic status, severity of asthma, use of nasal steroids, number of sinus surgeries, or time since last surgery.
DISCUSSION
Although intense investigation has recently characterized ILC2s in patients with asthma, allergic rhinitis, and nasal polyposis, there are no reports evaluating changes in ILC2 Gating strategy for nasal scrapings and blood ILC2s. The nasal scraping gating strategy was derived from polyp data (see Fig E3) . A, Representative nasal sample ILC2 gating from a postdesensitization sample in a patient with AERD. ILC2s were identified as CD45 numbers in patients with AERD during NSAID reactions. Our novel findings demonstrate that ILC2s are recruited to the nasal mucosa during COX-1 inhibitor-induced reactions in patients with AERD and that the increase in nasal ILC2 numbers from baseline correlates with reaction symptom severity. Concomitantly, ILC2 numbers were reduced in peripheral blood along with eosinophil numbers during NSAID reactions and correlated inversely with duration of the NSAID reaction. Furthermore, levels of lipid mediators that could recruit and activate ILC2s in tissues, including LTE 4 and PGD 2 metabolite, were increased in urine during reactions. ILC2s are activated by PGD 2 and capable of producing large amounts of type 2 cytokines, leading to tissue eosinophilia. 10, 13, 20 Importantly, AERD is also associated with these characteristics, and we postulated that ILC2s might be active in patients with the disease. In this study we found that after ketorolac challenge-induced reactions in patients with AERD, blood ILC2 numbers decreased with a concurrent increase in nasal scraping ILC2 numbers. These changes were contemporaneous with an increase in levels of the stable PGD 2 metabolite 11b-PGF 2 a and the terminal CysLT LTE 4 . PGD 2 and LTE 4 levels are increased at baseline in patients with AERD and increase after COX-1 inhibitor ingestion, 5, 25 and PGD 2 has been shown to promote chemotaxis in ILC2s. 10, 20 Notably, CysLTs have been shown to be chemotactic for T H 2 cells 26 and eosinophils 27 and could be contributing also to the ILC2 responses we observed. Numbers of blood ILC2s during reactions negatively correlated with the time it took for the reactions to subside, which could be due to ongoing ILC2 recruitment during more severe reactions, but this hypothesis will require further study.
Changes in nasal mucosal ILC2 numbers also correlated positively with severity of symptoms during reactions. Buchheit et al 7 reported that increased nasal symptoms in patients with AERD correlated with peak levels of a PGD 2 metabolite, which could promote ILC2 recruitment and activation. These data also indicate that subjective patient symptoms, particularly nasoocular symptoms, can be correlated with objective laboratory measurements of reaction intensity. Although nasal mucosal ILC2 numbers correlated with reaction severity in our studies, we were unable to show a correlation between change in ILC2 numbers and change in FEV 1 . There might be several reasons for this finding. First, all of our patients were taking a leukotriene Change between baseline and reaction samples was significant (P 5 .001, paired t test), as well as between reaction and postdesensitization samples (P 5 .004, paired t test). B, Change in percentage of ILC2s from enriched PBMCs before challenge, during reaction, and after desensitization was complete (post). Change between baseline and reaction samples was significant (P 5 .031, paired t test). C, Normalized values for nasal scraping and blood ILC2s at the 3 times points. Solid line is for patients with AERD, and dotted lines are for control subjects. D, Eosinophils as percentage of enriched granulocytes. Difference between baseline and reaction samples was significant (P 5 .044, paired t test). E, Change in levels of the urine PGD 2 metabolite 11b-PGF 2 a. Difference between baseline and reaction samples was significant (P 5 .008). F, Change in urine LTE 4 levels. Difference between baseline and reaction sample was significant (P 5 .017). *P < .05 and **P < .005. modifier for at least 1 week, which has been shown to reduce the drop in FEV 1 after aspirin challenge, leading to more upper airway-only reactions. 28 Second, all patients were first challenged/desensitized to nasal ketorolac, which also limits lower airway reactions. 22 Finally, nasal recruitment of ILC2s might not be completely representative of recruitment and activation of lung ILC2s during AERD reactions.
At the end of the clinical desensitization, we did not observe a consistent pattern of changes in blood ILC2 or eosinophil numbers because values remained low in some patients, whereas others increased back to predesensitization levels. The difference in aspirin dose and protocol duration could contribute to some of this variability, although subgroup analysis with small numbers of patients continued to show a lack of consistent responses in postdesensitization ILC2 and eosinophil numbers. These individual differences did not correlate with systemic steroid use, which could have an effect on ILC2 numbers. 19 Those patients who had symptoms on the last day had a trend toward lower ILC2 numbers in their blood, although this fell short of significance. The differences in postdesensitization levels might be due to ongoing mast cell activation, as noted by continued symptoms, and recruitment of ILC2s into the tissue. Indeed, one mechanism by which aspirin desensitization might work is by preventing cells from homing into the tissues. 29 PGD 2 levels are increased in mast cells from patients with AERD, 7 and high doses of aspirin are able to block both COX-1 and COX-2, which might allow for prevention of high amounts of PGD 2 . Cahill et al 29 showed that PGD 2 levels decrease after aspirin desensitization and blood eosinophil numbers actually increase in the blood over time, presumably because of loss of the PGD 2 gradient. Whether there is also an increase in blood ILC2 numbers is not known. Previous work has shown that AERD can be mediated by innate type 2 immunity. First, the potency of the COX-1 inhibition determines the severity of the reaction, which indicates that it is not adaptive recognition of a specific drug structure that activates the immune system. 30 Second, 2 danger signals released from epithelial cells, IL-33, an alarmin-like cytokine, and TSLP, an IL-7-like cytokine, have been shown to be upregulated in nasal polyps from patients with AERD and important drivers for COX-1 inhibitor-induced reactions. 7, 8, 31 In a mouse model, blockage of IL-33 abrogated the change in airway resistance and cytokine release after aspirin-lysine challenge, 8 which supports in vitro studies that showed IL-33 alone can induce human mast cell cytokine production. 32 Dysregulation of the leukotriene pathway contributes to the pathogenesis of AERD, 6 and IL-33 expression was found to be dependent on leukotrienes acting on epithelial cells. High PGD 2 levels are characteristic of AERD, and Buchheit et al 7 showed that TSLP was able to induce PGD 2 generation in vitro. Interestingly, IL-33 and TSLP strongly activate ILC2s to produce cytokines capable of driving eosinophilia independently of adaptive immunity. 11, 12 ILC2s also express CyLT1R and generate cytokines in response to stimulation with CysLTs. 9 Thus, although we have suggested that PGD 2 might be a key mediator for ILC2 influx into the nose, it is possible that IL-33, TSLP, and/or CysLTs are also contributing. The role of ILC2s after recruitment into tissue is not clear, although the cytokines produced by ILC2s can promote several features of AERD, including eosinophilia and airway hyperresponsiveness. 33 Intensely eosinophilic mucosal tissues is one of the disease's hallmarks, and ILC2s produce abundant amounts of IL-5, which is the major promoter of eosinophils. 34 Furthermore, IL-9 is also produced by ILC2s, which contributes to mast cell accumulation and mucus production in animal asthma models. 35 Interestingly, both mast cells and eosinophils are an important source of PGD 2 , 36 indicating a reciprocal relationship between ILC2s and these cell populations. Thus, ILC2s are a good candidate to support the prominent eosinophilic inflammation and mast cell activation seen in patients with AERD, especially given the lack of requirement for specific antigen.
We were able to replicate earlier data that showed a decrease in blood eosinophil numbers after aspirin challenge. 6, 7 Eosinophils have been studied considerably in patients with AERD. Eosinophils, which express CRTH2, respond to PGD 2 by undergoing chemotaxis that can be blocked with a CRTH2 antagonist. 37 Eosinophil numbers decrease in the blood of patients with AERD after aspirin challenge, 6 ,7 presumably because they are migrating to the tissue in response to the high levels of PGD 2 released during these reactions. Indeed, eosinophil numbers have been shown to increase in nasal lavage fluid after nasal lysine-aspirin challenge in patients with AERD, 38 although in this previous study blood eosinophil numbers were not measured to show whether a corresponding decrease occurs. ILC2s also express CRTH2 and undergo chemotaxis in response to PGD 2 in vitro, 10 and we hypothesized that they can migrate in response to the high levels of PGD 2 made during COX-1 inhibitor-provoked reactions.
We did not find a direct correlation between increases in ILC2 numbers in tissue and decreases in peripheral blood ILC2 or eosinophil numbers. This could be due to several factors. First, animal studies have shown that ILC2s are recruited from the bone marrow, and the kinetics of replenishment in human subjects is currently unknown. 13 Furthermore, there might be many more ILC2s in the blood versus the nasal mucosa, and a small change in circulating ILC2 numbers could lead to a much larger change in the nose. Thus a direct inverse correlation might not have been detected because of disproportionate changes in both compartments (nose vs blood), replenishment from bone marrow, and recruitment to other tissues (lung, gastrointestinal tract, and skin) during reactions.
Although our findings are novel in connecting ILC2s to AERD, there are several limitations of our investigations. First, we did not perform functional studies of nasal ILC2s because of very limited cell numbers. Second, CRTH2 was used to identify nasal scraping ILC2s, which can be downregulated in the presence of PGD 2 . 7, 10 However, CRTH2 has been shown to be the most specific marker for human ILC2s, 39 and we have not reliably found other surface markers, including IL-33 receptor, to be useful. Finally, all of the patients were taking leukotriene modifiers drugs, which have been shown to decrease the airway response seen after aspirin challenge. 28 Naso-ocular symptoms are not typically blocked by these drugs, but it is possible that these agents blunted ILC2 recruitment.
In summary, the patients with AERD we studied had increased ILC2 numbers in nasal scrapings and decreased numbers in blood during COX-1 inhibitor challenges, which also corresponded to increases in urinary 11b-PGF 2 a levels and severity of symptoms.
Thus, ILC2s are recruited to the nasal mucosa in patients with AERD and could contribute to pathogenesis through production of T H 2 cytokines.
We thank Dr Katherine Woessner and the nursing staff at Scripps Clinic and University of Southern California, San Diego.
Key messages
d ILC2 numbers increased in nasal mucosa and decreased in blood during COX-1 inhibitor reactions in patients with AERD.
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